ASH's 2025 meeting ended with strong multiple myeloma data from J&J, a new treatment for a rare disorder, and strains on a ...

In today's D.C. Diagnosis newsletter, the Biosecure Act advances, but extra ACA subsidies are still up in the air.

Today we discuss why comparing U.S. vaccine policy to Europe’s is a red herring, why the revolving door at the FDA between ...

In this morning's Pharmalittle roundup, we're reading about FDA scrutiny of RSV therapies, an AI tool for clinical trials, ...

Kids and teenagers with spinal muscular atrophy had more mobility after receiving a single-dose gene replacement therapy, ...

Radiology was an early adopter of AI technology but as researchers and startups forge ahead lean with a new wave of the ...

Nothing corrodes public trust in a regulatory agency faster than the sense that its senior officials are auditioning for ...

The FDA drug center’s new acting director Tracy Beth Høeg fits a pattern of risky, internal contradictions among agency ...

The chaos created by the freezing and termination of billions of dollars of research grants has left trans academics ...

If any ambiguity remained about the ultimate goal of the current administration’s public health policy, last week shattered ...

Terns Pharmaceuticals reports its targeted leukemia drug maintained and even boosted molecular response rates in ...

The ASH meeting included positive early results about a Terns drug for chronic myeloid leukemia and a Kura menin-blocker for ...